Scedosporium infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:07:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Scedosporium infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults https://clinicaltrials.eu/trial/study-of-fosmanogepix-compared-to-standard-antifungal-drugs-for-treating-invasive-mold-infections-in-adults/ Wed, 29 Apr 2026 15:06:23 +0000 https://clinicaltrials.eu/trial/study-of-fosmanogepix-compared-to-standard-antifungal-drugs-for-treating-invasive-mold-infections-in-adults/ This study focuses on treating invasive mold infections caused by various types of fungi, including Aspergillus, Fusarium, Lomentospora prolificans, and Mucorales fungi. The main treatment being tested is fosmanogepix, which will be given both as an infusion into a vein and as tablets by mouth. The study will compare fosmanogepix with other antifungal medications including voriconazole, anidulafungin, amphotericin B, rezafungin, micafungin, caspofungin, isavuconazole, posaconazole, and terbinafine.

The purpose of this research is to evaluate how well fosmanogepix works and how safe it is for treating adults who have serious fungal infections. The study will look at whether the treatment helps patients survive and recover from their infections. The treatment period can last up to 180 days, depending on how each patient responds.

During the study, doctors will monitor patients’ progress through various tests and examinations. They will check how well the infection responds to treatment by looking at clinical symptoms, laboratory tests, and imaging scans. They will also carefully track any side effects that may occur during treatment.

]]>